Chronic allograft nephropathy: An update

Kidney International

Volumn 56, Issue 3, 1999, Pages 783-793

  Paul, L C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; Graft injury; Immuno lymphatic theory; Renal transplantation; Transplant failure

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GRAFT REJECTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; STEROID THERAPY; TREATMENT OUTCOME;

EID: 0032844172     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00611.x     Document Type: Article

References (142)

1. 1. Gjertson DW: Survival trends in long-term first cadaver-donor kidney transplants, in Clinical Transplants 1991, edited by Terasaki PI, Cecka JM, Los Angeles, UCLA Tissue Typing Laboratory, 1991, p 225
2. 2. Paul LC: Chronic renal transplant loss. Kidney Int 47:1491-1499, 1995
3. 3. Schweitzer EJ, Matas AJ, Gillingham KJ, Payne WD, Gores PF, Dunn DL, Sutherland DER, Najarian JS: Causes of renal allograft loss: Progress in the 1980, challenges for the 1990s. Ann Surg 214:679-688, 1991
4. 4. Tilney NL, Paul LC: Antigen-independent events leading to chronic graft dysfunction, in Transplantation Biology: Cellular and Molecular Aspects, edited by Tilney NL, Strom TB, Paul LC, Philadelphia, New York, Lippincott-Raven, 1996, p 629
5. 5. Paul LC, Tilney NL: Alloantigen-dependent events in chronic rejection, in Transplantation Biology: Cellular and Molecular Aspects, edited by Tilney NL, Strom TB, Paul LC, Philadelphia, Lippincott-Raven, 1996, p 567
6. 6. Paul LC, Häyry P, Foegh M, Dennis MJ, Mihatsch MJ, Larsson E, Fellström B: Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: Joint proposal from the Fourth Alexis Carrel Conference on Chronic Rejection and Accelerated Arteriosclerosis in Transplanted Organs. Transplant Proc 25:2022-2023, 1993
7. 7. Riggio RR, Haschemeyer R, Suthanthiran M, Cheigh J, Tapia L, Stubenbord W, Miller I, Stenzel KH: Predictability of renal allograft failure time in long-term survivors: A hypothesis. Transplant Proc 17:2311-2313, 1985
8. 8. Kasiske BL, Heim-Duthoy KL, Tortorice KL, Rao KV: The variable nature of chronic declines in renal allograft function. Transplantation 51:330-334, 1991
9. 9. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL: Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors. Kidney Int 49:518-524, 1996
10. 10. Raine AEG: Does antihypertensive therapy modify chronic allograft failure? Kidney Int 48(Suppl 52):S107-S111, 1995
11. 11. Luo H, Nishioka T, Eigler NL, Forrester JS, Fishbein MC, Berglund H, Siegel RJ: Coronary artery restenosis after balloon angioplasty in humans is associated with circumferential coronary constriction. Arterioscler Thromb Vasc Biol 16:1393-1398, 1996
12. 12. Barrientos A, Portoles J, Herrero JA, Torralbo A, Prats D, Gutierrez-Millet V, Blanco J: Glomerular hyperfiltration as a nonimmunologic mechanism of progression of chronic renal rejection. Transplantation 57:753-756, 1994
13. 13. Cheigh JS, Mouradian J, Soliman M, Tapia L, Riggio RR, Stenzel KH, Rubin AL: Focal segmental glomerulosclerosis in renal transplants. Am J Kidney Dis 2:449-455, 1983
14. 14. Hamburger J, Crosnier J, Dormont JA: Observations in patients with a well tolerated homotransplanted kidney. Ann NY Acad Sci 120:558-577, 1964
15. 15. Olsen TS: Pathology of allograft rejection, in Kidney Transplant Rejection: Diagnosis and Treatment, edited by Burdick JF, Racusen LC, Solez, K, Williams GM, New York, Basel, Hong Kong, Marcel Dekker, 1992, p 333
16. 16. Habib R, Antigua C, Hinglais N, Gagnadoux MF, Broyer M: Glomerular lesions in the transplanted kidney in children, Am J Kidney Dis 10:198-207, 1987
17. 17. Monga G, Mazzucco G, Messina M, Motta M, Quaranta S, Novara R: Intertubular capillary changes in kidney allografts: A morphologic investigation on 61 renal specimens. Mod Pathol 5:125-130, 1992
18. 18. Ivanyi B, Fahmy H, Szenoiiradszky P, Hansen H, Olsen S, Halloran P, Solez K: Peritubular capillary basement membrane changes in chronic renal allograft rejection. Transplant Proc (in press)
19. 19. Gould VE, Martinez-Lacabe V, Virtanen I, Sahlin KM, Schwartz MM: Differential distribution of tenascin and cellular fibronectins in acute and chronic renal allograft rejection. Lab Invest 67:71-79, 1992
20. 20. Habib R, Zurowska A, Hinglais N, Gubler M-C, Antignac C, Niaudet P, Broyer M, Gagnadoux M-F: A specific glomerular lesion of the graft: allograft glomerulopathy. Kidney Int 44(Suppl 42):S104-S111, 1993
21. 21. Koukoulis GK, Gould VE, Bhattacharyya A, Gould JE, Howeedy AA, Virtanen I: Tenascin in normal, reactive, hyperplastic and neoplastic tissues: Biologic and pathologic implications. Hum Pathol 22:636-643, 1991
22. 22. Vleming L-J, Baelde JJ, Westendorp RGJ, Daha MR, Van Es LA, Bruijn JA: Progression of chronic renal disease in humans is associated with the deposition of basement membrane components and decorin in the interstitial extracellular matrix. Clin Nephrol 44:211-219, 1995
23. 23. Abrass CK, Berfield AK, Stehman-Breen C, Alpers CE, Davis CL: Unique changes in interstitial extracellular matrix composition are associated with rejection and cyclosporine toxicity in human renal allograft biopsies. Am J Kidney Dis 33:11-20, 1999
24. 24. Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Crocker BP, Droz D, Dunmill MS, Halloran PF, Häyry P, Jennette JC, Keown PA, Marcussen N, Mihatsch MJ, Morozami K, Myers BD, Nast CC, Olsen CC, Racusen LC, Ramos EL, Rosen S, Sachs DH, Salomon DR, Sanfilippo F, Verani R, Von Willebrand E, Yamaguchi Y: International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff 97 working classification of kidney transplant pathology. Kidney Int 44:411-422, 1993
25. 25. Solez K, Benediktsson H, Cavallo T, Croker B, Demetris AJ, Drachenberg C, Emancipator S, Furness PN, Gaber LW, Gibson IW, Gough J, Gupta R, Halloran P, Häyry P, Kashgarian M, Marcussen N, Massy ZA, Mihatsch MJ, Morozumi K, Noronha I, Olsen S, Papadimitriou J, Paul LC, Picken M: Report of the third Banff conference on allograft pathology (July 20-24, 1995) on classification and lesion scoring in renal allograft pathology. Transplant Proc 28:441-444, 1996
26. 26. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro M-C, Cavallo T, Croker BP, Demetris AJ, Drachtenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Häyry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad A, Marcussfn N, Mihatsch MJ, Nadasdy T, Nickerson P, Olsen TS, Papaditriou JC, Randhawa PS, Rayer DC, Roberts I, Rose S, Rush D, Salinas-Madrigal L, Salomon DR, Sund S, Taskinen E, Trpkov K, Yamaguchi Y: The Banff 97 working classification of renal allograft pathology. Kidney Int 55:713-723, 1999
27. 27. Nicholson ML, Harper SJ, Wheatly TJ, Mcculloch TA, Feehally J, Furness PN: Renal transplant fibrosis: Histomorphometric assessment of early renal transplant biopsies for markers of chronic rejection. Transplant Proc 29:2793-2794, 1997
28. 28. Gjertson DW: A multi-factor analysis of kidney graft outcomes at one and five years posttransplantation: 1996 UNOS update, in Clinical Transplants 1996, edited by Cecka JM, Terasaki PI, Los Angeles, UCLA Tissue Typing Laboratory, 1997, p 343
29. 29. Terasaki PI, Gjertson DW, Cecka JM, Takemoto S, Cho YW: Significance of the donor age effect on kidney transplants. Clin Transpl 11:366-372, 1997
30. 30. Shoskes D, Cecka M: Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 55:1697-1701, 1998
31. 31. Almond PS, Matas A, Gillingham KJ, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS: Risk factors for chronic rejection in renal allograft recipients. Transplantation 55:752-757, 1993
32. 32. Matas AJ, Gillingham KJ, Payne WD, Najarian JS: The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 57:857-859, 1994
33. 3. Van Saase JLCM, Van Der Woude FJ, Thorogood J, Hollander AAMJ, Van Esla, Weening JJ, Van Bockel JH, Bruijn JA: The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation 59:1280-1285, 1995
34. 34. Nickelett V, Vamvakas EC, Pascual M, Poletti RJ, Colvin RB: The prognostic significance of specific arterial lesions in acute renal allograft rejection. J Am Soc Nephrol 9:1301-1308, 1998
35. 35. Alexopoulos E, Leontsini M, Papadimitriou M: Macrophages and HLA-DR ( 1 ) cells in acutely rejecting kidney transplants predict subsequent graft survival, even after reversal of the acute episode. Nephrologie 4:113-117, 1998
36. 36. Dimény E, Wahlberg J, Lithett H, Fellström B: Hyperlipidaemia in renal transplantation - Risk factor for long-term graft outcome. Eur J Clin Invest 25:574-583, 1995
37. 37. Brazy PC, Pirsch JD, Belzer FO: Factors affecting renal allograft function in long-term recipients. Am J Kidney Dis 19:558-566, 1992
38. 38. Opelz G, Wujciak T, Ritz E, Collaborative Transplant Study: Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 53:217-222, 1998
39. 39. Opelz G: Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. Transplant Proc 29:73-76, 1997
40. 40. Kupin W, Nakhleh R, Lee M, Venkat KK, Goggins M, Mozes M, Escobar F, Abouljoud M: Separate risk factors for the development of transplant glomerulopathy vs chronic tubulointerstitial rejection. Transplant Proc 29:245-246, 1997
41. 41. Terasaki PI, Cecka JM, Gjertson DW, Cho Y, Takemoto S, Cohn M: A ten year prediction for kidney transplant survival, in Clinical Transplant 1992, ediled by Terasaki PI, Cecka JM, Los Angeles, UCLA Tissue Typing Laboratory, 1992, p 501
42. 42. Myers BD, Ross J, Newton L, Leutscher J, Perlroth M: Cyclosporine-associated chronic nephropathy. N Engl J Med 311:699-705, 1984
43. 43. Burke JF, Pirsch JD, Ramos EL, Salomon DR, Stablein DM, Van Buren DH, West JC: Long-term efficacy and safety of cyclosporine in renal-transplant patients. N Engl J Med 331:358 363, 1994
44. 44. Randhawa PS, Tsamandas AC, Magnone M, Jordan M, Shapiro R, Starzl TE, Demetris AJ: Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. Am J Surg Pathol 20:306-312, 1996
45. 45. Connolly JO, Gane E, Higgins RM, O'Donnell PJ, Devlin J, Scoble JE, Williams R: Renal arteriopathy associated with FK506 therapy following liver transplantation. Nephrol Dial Transplant 9:834-836, 1994
46. 46. Garcia DL, Rennke HG, Brenner BM, Anderson S: Chronic glucocorticoid therapy amplilies glomerular injury in rats with renal ablation. J Clin Invest 80:867-874, 1987
47. 47. Opelz G: Effect of maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation 58:443-446, 1994
48. 48. Opelz G: Influence of treatment with cyclosporine, azathioprine and steroids on chronic allograft failure. Kidney Int 48(Suppl 52):S89-S92, 1995
49. 49. Sinclair NR: Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. Can Med Assoc J 147:645-657, 1992
50. 50. Hollander AAMJ, Hene RJ, Hermans J, Van Es LA, Van Der Woude FJ: Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: A randomized trial. J Am Soc Nephrol 8:294-301, 1997
51. 51. Massy ZA, Guijarro C, Kasiske BL: Clinical predictors of chronic renal allograft rejection. Kidney Int 48(Suppl 52):S85-S88, 1995
52. 52. Grinyo JM, Gil-Vernei S, Serón D, Cruzado JM, Moreso F, Fulladosa X, Castflao AM, Torras J, Hooftman L, Alsina J: Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. Transplantation 63:1688-1690, 1997
53. 53. Kunz R, Neumayer HH: Maintenance therapy with triple versus double immunosuppressive regimen in renal transplantation: A meta-analysis. Transplantation 63:386-392, 1997
54. 54. Griffin PJA, Salaman JR: Long-term results of cyclosporine monotherapy in kidney transplantation. Transplant Proc 23:992-993, 1991
55. 55. Amenábar JJ, Gómez-Ullate P, García-López FJ, Aurrecoechea B, García-Erauzkin G, Lampreabe I: A randomized trial comparing cyclosporine and steroids with cyclosporine, azathioprine, and steroids in cadaveric renal transplantation. Transplantation 65:653-661, 1998
56. 56. Paul LC, Zaltzman J, Cardella CJ: Prophylactic anti-lymphocyte antibody therapy in kidney transplantation: Quo vadis? Transplant Rev 9:200-206, 1995
57. 57. Cecka JM, Gjertson D, Terasaki PI: Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups? Transplant Proc 25:548-549, 1993
58. 58. Opelz G: Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation 60:1220-1224, 1995
59. 59. Szczech LA, Berlin JA, Aradhye S, Grossman RA, Feldman HI: Effect of anti-lymphocyte induction therapy on renal allograft survival: A meta-analysis. J Am Soc Nephrol 8:1771-1777, 1997
60. 60. Szczech LA, Berlin JA, Feldman HI: Anti-lymphocyte antibody induct therapy: The effect of antilymphocyte induction therapy on renal allograft survival: A meta-analysis of individual patient-level data. Ann Intern Med 128:817-826, 1998
61. 61. Halloran P, Mathew T, Tomlanovich S, Groih C, Hooftman L, Barker C: Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 63:39-47, 1997
62. 62. Mathew TH, Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years. Transplantation 65:1450-1454, 1998
63. 63. Thorogood J, Van Houwelingen HC, Van Rood JJ, Zantvoort FA, Schreuder GMT, Persijn GG: Long-term results of kidney transplantation in Eurotransplant, in Organ Transplantation: Long-Term Results, edited by Paul LC, Solez K, New York, Basel, Hong Kong, Marcel Dekker, 1992, p 33
64. 64. Vanrenterghem Y, Peeters J: Impact of cyclosporine on chronic rejection and graft vasculopathy. Transplant Proc 26:2560-2563, 1994
65. 65. Kasiske BL, Heim-Duthoy K, Ma JZ: Elective cyclosporine withdrawal after renal transplantation: A meta-analysis. JAMA 269:395-400, 1993
66. 66. Hollander AAMJ, Van Saase JLCM, Kootte AMM, Van Dorp WT, Van Bockel HJ, Van Es LA, Van Der Woude FJ: Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 345:610-614, 1995
67. 67. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS, FK506 Kidney Transplant Study Group: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 63:977-983, 1997
68. 68. Gjertson DW, Cecka JM, Terasaki PI: The relative effects of FK506 and cyclosporine on short-and long-term kidney graft survival. Transplantation 60:1384-1388, 1995
69. 69. Katznelson S, Cecka JM: Immunosuppressive regimens and their effects on renal allograft outcome, in Clinical Transplants 1996, edited by Cecka JM, Terasaki PI, Los Angeles, UCLA Tissue Typing Laboratory, 1996, p 361
70. 70. Sollinger HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60:225-232, 1995
71. 71. The European Mycophenolate Mofetil Cooperative Study Group: Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345:1321-1326, 1995
72. 72. Tricontinental Mycophenolate Mofetil Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61:1029-1037, 1996
73. 73. Simonson MS, Emancipator SN, Knauss T, Hricik DE: Elevated neointimal endothelin-1 in transplantation-associated arteriosclerosis of renal allograft recipients. Kidney Int 54:960-971, 1998
74. 74. Wilson AG, Di Giovine FS, Blakemore AI, Duff GW: Single base polymorphism in the human tumour necrosis factor alpha (TNF-α) gene detectable by Nco 1 restriction of PCR product. Hum Mol Genet 1:353, 1992
75. 75. Hutchinson IV, Turner DM, Sankaran D, Awad MR, Sinnott PJ: Influence of cytokine genotypes on allograft rejection. Transplant Proc 30:862-863, 1998
76. 76. Eskdale J, Gallagher G, Verweij CL, Keusers V, Westendorp RGJ, Huizinga TWJ: Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 95:9465-9470, 1998
77. 77. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 241:F85-F93, 1981
78. 78. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38:384-394, 1990
79. 79. Yoshida Y, Fogo A, Ichikawa I: Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int 35:654-664, 1989
80. 80. Nath KA, Hostetter MK, Hostetter TH: Pathophysiology of chronic tubulo-interstitial disease in rats: Interactions of dietary acid load, ammonia and complement component C3. J Clin Invest 76:667-675, 1985
81. 81. Alfrey AC: Role of iron and oxygen radicals in the progression of chronic renal failure. Am J Kidney Dis 23:183-187, 1994
82. 82. Keane WF, Kasiske BL, O'Donnell MP: Lipids and progressive glomerulosclerosis. Am J Nephrol 8:261-271, 1988
83. 83. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 51:2-15, 1997
84. 84. Eddy AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7:2495-2508, 1996
85. 85. Kingma I, Chea R, Davidoff A, Benediktsson H, Paul LC: Glomerular capillary pressures in long-surviving rat renal allografts. Transplantation 56:53-60, 1993
86. 86. Junaid A, Kren SM, Rosenberg MF, Nath KA, Hostetter TH: Physiological and structural responses to chronic experimental renal allograft injury. Am J Physiol 267:F1102-F1107, 1995
87. 87. Mackenzie HS, Azuma H, Rennke HG, Tilney NL, Brenner BM: Renal mass as a determinant of late allograft outcome: Insights from experimental studies in rats. Kidney Int 48(Suppl 52):S38-S42, 1995
88. 88. Benediktsson H, Chea R, Davidoff A, Paul LC: Antihypertensive drug treatment in chronic renal allograft rejection in the rat: Effect on structure and function. Transplantation 62:1634-1642, 1996
89. 89. Mackenzie HS, Tullius SG, Heemann UW, Azuma H, Rennke HG, Brenner BM, Tilney NL: Nephron supply is a major determinant of long-term renal allograft outcome in rats. J Clin Invest 94:2148-2152, 1994
90. 90. Brenner BM, Cohen RA, Milford EL: In renal transplantation, one size may not fit all. J Am Soc Nephrol 3:162-169, 1992
91. 91. Terasaki PI, Koyama H, Cecka JM, Gjertson DW:The hyperfiltration hypothesis in human renal transplantation. Transplantation 57:1450-1454, 1994
92. 92. Feldman HI, Faziol I, Roth D, Berlin JA, Brayman K, Burns JE, Grossman RA: Recipient body size and cadaveric renal allograft survival. J Am Soc Nephrol 7:151-157, 1996
93. 93. Pirsch JD, Armbrust MJ, Knechtle SJ, D'Alessandro AM, Sollinger HW, Heisey DM, Belzer FO: Obesity as a risk factor following renal transplantation. Transplantation 59:631-633, 1995
94. 94. Halloran PF, Melk A, Barth C: Rethinking chronic allograft nephropathy: The concept of accelerated senescence. J Am Soc Nephrol 10:167-181, 1999
95. 95. Salahudeen AK, Hostetter TH, Raatz SK, Rosenberg ME: Effects of dietary protein in patients with chronic renal transplant rejection. Kidney Int 41:183-190, 1992
96. 96. Rosenberg ME, Salahudeen AK, Hostetter TH: Dietary protein and the renin-angiotensin system in chronic renal allograft rejection. Kidney Int 48(Suppl 52):S102-S106, 1995
97. 97. Amuchastegui SC, Azzollini N, Mister M, Pezzotta A, Perico N, Remuzzi G: Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 9:1948-1955, 1998
98. 98. Remuzzi G, Perico N: Protecting single-kidney allografts from long-term functional deterioration. J Am Soc Nephrol 9:1321-1332, 1998
99. 99. Ross R: The pathogenesis of atherosclerosis: Perspective for the 1990s. Nature 362:801-809, 1993
100. 100. Demetris AJ, Murase N, Ye Q, Galvao FHF, Richeri C, Saad R, Pham S, Duquesnoy RJ, Zeevi A, Fung JJ, Starzl TE: Analysis of chronic rejection and obliterative arteriopathy: Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol 150:563-578, 1997
101. 101. Malek P, Vrubel J, Kolc J: Lymphatic aspects of experimental and clinical transplantation. Bull Soc Int Chirurgie 28:110-114, 1969
102. 102. Eliska O, Elisková P, Mirejovsky M: Lymph vessels of the transplanted kidney. Nephron 44:136-141, 1986
103. 103. Cockett ATK, Sakai A, Netto ICV: Kidney lymphatics: An important network in transplantation. Trans Am Assoc Gen-Urin Surgeons 65:73-76, 1973
104. 104. Souti F, Jellinek H, Schneider F, Lengyel F, Berczi V, Kekesi V: Lymphatic arteriopathy: Damage to the wall of the canine femoral artery after lymphatic blockade. Lymphology 24:54-59, 1991
105. 105. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV: Genotypic variation in the transforming growth factor-β1 gene: Association with transforming growth factor-beta production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66:1014-1020, 1998
106. 106. Shihab FS, Yamamoto T, Nast CC, Cohen AH, Noble NA, Gold LI, Border WA: Transforming, growth factor-β and matrix protein expression in acute and chronic rejection of human renal allografts. J Am Soc Nephrol 6:286-294, 1995
107. 107. Paul LC, Saito K, Davidoff A, Benediktsson H: Growth factor transcripts in rat renal transplants. Am J Kidney Dis 28:441-450, 1996
108. 108. Roy-Chaudhury P, Simpson JG, Power DA: Endoglin, a transforming growth factor-beta-binding protein, is upregulated in chronic progressive renal disease. Exp Nephrol 5:55-60, 1997
109. 109. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E: Natural inhihitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 360:361-364, 1992
110. 110. Tang W-H, Friess H, Di Mola FF, Schilling M, Maurer C, Graber HU, Dervenis C, Zimmerman A, Büchler MW: Activation of the serine proteinase system in chronic kidney rejection. Transplantation 65:1628-1634, 1998
111. 111. Paul LC, Muralidharan J, Muzaffar SA, Manting EH, Valentin J-F, De Heer E, Kashgarian M: Antibodies against mesangial cells and their secretory products in chronic renal allograft rejection in the rat. Am J Pathol 152:1209-1223, 1998
112. 112. Huttenlocher A, Werb Z, Tremble P, Huhtala P, Rosenberg L, Damsky CH: Decorin regulates collagenase gene expression in fibroblasts adhering to vitronectin. Matrix Biol 15:239-250, 1996
113. 113. Simonson MS, Herman WH: Protein kinase C and protein tyrosine kinase activity contribute to mitogenic signalling by endothelin-1: Cross-talk between G protein-coupled receptors and pp60c-src. J Biol Chem 268:9347-9357, 1993
114. 114. Frisch SM, Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619-626, 1994
115. 115. STRUTZ F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JF, Neilson EG: Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 130:393-405, 1995
116. 116. Schelling JR, Nkemere N, Kopp JB, Cleveland RP: Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab Invest 78:813-824, 1998
117. 117. Wever PC, Boonstra JG, Laterveer JC, Hack CE, Van Der Woude FJ, Daha MR, Ten Berge IJM: Mechanisms of lymphocyte-mediated cytotoxicity in acute renal allograft rejection. Transplantation 66:259-264, 1998
118. 118. Paul LC, Van Es LA, Stuffers-Heiman M, De La Riviere GB, Kalff MW: Antibodies directed against tubular basement membranes in human renal allograft recipients. Clin Immunol Immunopathol 14:231-237, 1979
119. 119. De Heer F, Davidoff A, Van Der Wal A, Van Geest M, Paul LC: Chronic renal allograft rejection in the rat: Transplantation-induced antibodies against basement membrane antigens. Lab Invest 70:494-502, 1994
120. 120. Halloran PF: Non-immunologic tissue injury and stress in chronic allograft dysfunction. Graft 1:23-29, 1998
121. 121. Hayflick L, Moorhead PS: The serial cultivation of human diploid cell strains. Exp Cell Res 25:585-621, 1961
122. 122. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, Winn KJ, Pearson TC: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381:434-438, 1996
123. 123. Azuma H, Chandraker A, Nadeau K, Hancock WW, Carpenter CB, Tilney NL, Sayegh MH: Blockade of T-cell costimulalion prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci USA 93:12439-12444, 1996
124. 124. Azuma H, Binder J, Heemann U, Tullius SG,Tilney NL: Effect of RS61443 on chronic rejection of rat kidney allografts. Transplant Proc 27:436-437, 1995
125. 125. Schmid C, Heemann U, Azuma H, Tilney NL: Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts. Transplantation 60:729-733, 1995
126. 126. Häyry P, Isoniemi H, Yilmaz S, Mennander A, Lemström K, Räisänen-Sokolowski A, Koskinen P, Ustinov J, Lautenschlager I, Taskinen E, Krogerus L, Aho P, Paavonen T: Chronic allograft rejection. Immunol Rev 134:33-81, 1993
127. 127. Aziz S, Tada Y, Gordon D, Mcdonald TO, Fareed J, Verrier ED: A reduction in accelerated graft coronary disease and an improvement in cardiac allograft survival using low molecular weight heparin in combination with cyclosporine. J Heart Lung Transplant 12:634-643, 1993
128. 128. Häyry P, Räisänen A, Ustinov J, Mennander A, Paavonen T: Somatostatin analog Lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis. FASEB J 7:1055-1060, 1993
129. 129. Häyry P, Myllärniemi M, Aavik E, Alatalo S, Aho P, Yilmaz S, Räisänen-Sokolowski A, Cozzone G, Jameson BA, Baserga R: Stable D-peptide analogue of insulin-like growth factor-1 inhibits smooth muscle proliferation after carotid ballooning injury in the rat. FASEB J 9:1336-1344, 1995
130. 130. Furukawa Y, Matsumori A, Hirozane T, Sasayama S: Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model: A comparative study with captopril. Circulation 93:333-339, 1996
131. 131. Lou H, Kodama T, Zhao YJ, Maurice P, Wang YN, Katz N, Foegh ML: Inhibition of transplant coronary arteriosclerosis in rabbits by chronic estradiol treatment is associated with abolition of MHC class II antigen expression. Circulation 94:3355-3361, 1996
132. 132. Lou H, Kodama T, Wang YN, Katz N, Ramwell P, Foegh ML: L-arginine prevents heart transplant arteriosclerosis by modulating the vascular cell proliferative response to insulin-like growth factor-1 and interleukin-6. J Heart Lung Transplant 15:1248-1257, 1996
133. 133. Barnas U, Schmidt A, Haas M, Oberbauer R, Mayer G: The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure. Nephrol Dial Transplant 11:1822-1824, 1996
134. 134. Kasiske BL, Massy ZA, Guijarro C, Ma JZ: Chronic renal allograft rejection and clinical trial design. Kidney Int 48(Suppl 52):S116-S119, 1995
135. 135. Paul LC, Supkens YU: Surrogate end-points in chronic kidney graft rejection studies. Transplant Proc 31:1293-1294, 1999
136. 136. Land W: The potential impact of the reperfusion injury on acute and chronic rejection events following organ transplantation. Transplant Proc 26:3169-3171, 1994
137. 137. Myllärniemi M, Räisänen-Sokolowski A, Vuoristo P, Kallio E, Land W, Häyry P: Lack of effect of recombinant human superoxide dismutase on cold ischemia-induced arteriosclerosis in syngeneic rat aortic transplants. Transplantation 61:1018-1022, 1996
138. 138. Arend SM, Mallat MJK, Westendorp RJW, Van Der Woude FJ, Van Es LA: Patient survival after renal transplantation: more than 25 years follow up. Nephrol Dial Transplant 12:1672-1679, 1997
139. 139. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7:158-165, 1996
140. 140. Kobashigawa JA, Kasiske BL: Hyperlipidemia in solid organ transplantation. Transplantation 63:331-338, 1997
141. 141. Arnadottir M, Berg A-L: Treatment of hyperlipidemia in renal transplant recipients. Transplantation 63:339-345, 1997
142. 142. Bittar AC, Keitel E, Garcia CD, Bruno RM, Silviera AE, Messias A, Garcia VD: Patient non-compliance as a cause of late kidney graft failure. Transplant Proc 24:2720-2721, 1992